Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.48 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171445 | 0.88 | GSK3B (0.57) | BRAFITKGSK3AGSK3BCCNT1 | |
| SCHEMBL4177633 | 0.88 | BRAF (0.52) | BRAFITKGSK3AGSK3BJAK2 | |
| SCHEMBL4021105 | 0.86 | BRAF (0.53) | BRAFITKGSK3BPIM1PIM3 | |
| SCHEMBL4013453 | 0.85 | JAK2 (0.47) | BRAFITKGSK3AGSK3BCCNT1 | |
| SCHEMBL4175545 | 0.84 | BRAF (0.58) | BRAFITKGSK3AGSK3BJAK2 | |
| SCHEMBL13663484 | 0.82 | JAK2 (0.49) | BRAFITKGSK3BJAK2JAK3 | |
| SCHEMBL4020077 | 0.81 | CCNT1 (0.47) | ITKGSK3AGSK3BCCNT1CDK9 | |
| SCHEMBL13663495 | 0.79 | JAK2 (0.62) | ITKGSK3AGSK3BJAK2JAK3 | |
| SCHEMBL4159207 | 0.79 | CCNT1 (0.48) | BRAFGSK3BCCNT1CDK9JAK2 | |
| SCHEMBL4170239 | 0.79 | JAK2 (0.44) | BRAFITKGSK3AGSK3BCCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2009-10-29 | — | — | US | claimed |
| WO-2009089042-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2009-07-16 | — | — | WO | claimed |
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | MAP3K1, MAP3K15, MAP3K5 | BRAF 73/4885ITK 951/4885GSK3A 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.